New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer

Author： Schønnemann Katrine R.   Yilmaz Mette   Andersen Maria   Pfeiffer Per  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.50, Iss.1, 2011-01, pp. : 151-152

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer

By Andersen Maria   Schønnemann Katrine R.   Yilmaz Mette   Jensen Helle A.   Vestermark Lene W.   Pfeiffer Per  

Acta Oncologica, Vol. 49, Iss. 8, 2010-11 ,pp. : 1246-1252

Informa Healthcare

Access to resources Recommend Favorite

Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study

By Santini Daniele   Vincenzi Bruno   Schiavon Gaia   Di Seri Marisa   Virzí Vladimir   Spalletta Bruno   Caricato Marco   Coppola Roberto   Tonini Giuseppe  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 613-620

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I Study Of Docetaxel, Oxaliplatin, & Capecitabine (DOC) As First-Line Therapy of Patients With Locally Advanced or Metastatic Adenocarcinoma of Stomach and GE Junction

By Malik Imtiaz   Bernal Pedro   Byrd Janet  

Cancer Investigation, Vol. 28, Iss. 8, 2010-09 ,pp. : 833-838

Informa Healthcare

Access to resources Recommend Favorite

A phase II study of capecitabine plus oxaliplatin (XELOX): A new first-line option in metastatic colorectal cancer

By Makatsoris Thomas   Kalofonos Haralabos   Aravantinos Gerasimos   Papadimitriou Christos   Kastritis Efstathios   Rigatos Sotirios   Xiros Nikolaos   Petsas Theodore   Economopoulos Theofanis   Sakadamis Athanassios   Fountzilas George  

International Journal of Gastrointestinal Cancer, Vol. 35, Iss. 2, 2005-04 ,pp. : 103-109

Humana Press, Inc

Access to resources Recommend Favorite

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)

By Raez Luis   Santos Edgardo   Webb R.   Wade James   Brito Roger   Karr Melissa   Kennah Andra   Childs Barrett  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1103-1110

Springer Publishing Company

Access to resources Recommend Favorite